Zydus Cadila has received the final approval from the USFDA to market Omeprazole and Sodium Bicarbonate Capsules 20 mg/1100 mg (OTC). The drug is used to treat certain stomach and esophagus problems (such as acid reflux, ulcers). It is also used to prevent stomach bleeding in very ill patients. It will be manufactured at the group's formulations manufacturing facility at Moraiya, Ahmedabad.
The group now has more than 180 approvals and has so far filed over 320 ANDAs since the commencement of the filing process in FY 2003-04.
Shares of CADILA HEALTHCARE LTD. was last trading in BSE at Rs.380.1 as compared to the previous close of Rs. 385.25. The total number of shares traded during the day was 29971 in over 746 trades.
The stock hit an intraday high of Rs. 386.6 and intraday low of 379. The net turnover during the day was Rs. 11460059.